Regeneron Commences Clinical Trial of Efficacy and Safety of VEGF Trap-Eye in Patients With Choroidal Neovascularisation (CNV) of the Retina
January 20, 2011
Regeneron and Bayer HealthCare recently announced initiation of a new Phase 3 clinical trial in collaboration with the Singapore Eye Research Institute (SERI) to investigate the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia. The trial has started in Japan and other Asian countries, including China, Korea, Singapore, and Taiwan.
Jump down to form below to submit your own comments